Effect of apolipoprotein E, peroxisome proliferator-activated receptor alpha and lipoprotein lipase gene mutations on the ability of fenofibrate to improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients.
Brisson D, Ledoux K, Bossé Y, St-Pierre J, Julien P, Perron P, Hudson TJ, Vohl MC, Gaudet D. Pharmacogenetics. 2002 Jun; 12(4):313-20.